

Accelerating Complex siRNA Programs from Discovery to Commercial Supply

siRNA is an emerging therapeutic modality that enables precise gene silencing at the mRNA level, unlocking new possibilities for targeted treatment.

We enable our clients to advance a broad spectrum of siRNA modalities, including complex conjugates, from discovery through to commercial supply.

Proven Expertise & Track Record

46,000+
compounds delivered in 2025

47
molecules supported from preclinical to commercial

53% clinical pipelines using both API and Drug Product services

Supporting **40%** of licensing and acquisition deals in the global market

Broad siRNA Conjugation Capabilities


- **15+** siRNA conjugation varieties
- Synthesis of **17,600+** siRNA-GaINAc, **10,200+** siRNA-Lipid

Enabling Technologies

- SPOS/LPOS
- API in solution
- Biocatalysis fragment ligation
- Ethanol precipitation
- Thin Film Evaporation (TFE)
- Continuous flow chromatography


[Case Study] Accelerating IND Timelines with Integrated CMC Solutions

Advanced a dual-target di-siRNA-GaINAc conjugate from PCC to IND CMC package in 8 months



Dual-Target Complexity | Parallel Activities | Streamlined Process | Accelerated Timeline

Why Partner with Us?



tides.wuxiapptec.com